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IS DENOSUMAB COST-EFFECTIVE COMPARED TO ORAL BISPHOSPHONATES 
FOR THE TREATMENT OF MALE OSTEOPOROSIS (MOP) IN SWEDEN?  
Parthan A1, Kruse MM1, Agodoa I2, Tao CY1, Silverman SL3, Orwoll E4 
1OptumInsight, Cambridge, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Cedars- 
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USA  
OBJECTIVES: Cost-effectiveness of denosumab versus oral bisphosphonates in 
MOP was evaluated from a third-party payer perspective in Sweden. METHODS: 
A lifetime cohort Markov model was developed to reflect osteoporotic health 
states. During each cycle, patients could have a fracture, remain healthy, remain 
in a post fracture state or die. Background fracture risks, mortality rates, 
persistence rates, utilities, medical and drug costs were derived using published 
sources. Bone mineral density (BMD) improvements have been shown to be 
similar between MOP and post-menopausal osteoporotic (PMO) populations, and 
a recent fracture trial showed zoledronate to have effects in men similar to those 
reported previously in women; therefore efficacy data from PMO women were 
used. Lifetime expected costs and quality-adjusted life-years (QALYs) were 
estimated for denosumab, generic alendronate, generic risedronate, and 
ibandronate. Patients in the model were 65-year-old men, with BMD T-score≤-
1.90 and prevalent vertebral fracture of 22.7%. In the base-case, the model 
assumed patients could receive treatment effects up to 2 years after 
discontinuation (offset time). Costs and QALYs were discounted at 3% annually. 
Extensive sensitivity analyses were conducted. RESULTS: Total lifetime costs for 
alendronate, denosumab, risedronate, and ibandronate were €45,118, €45,396, 
€45,526, and €46,523, respectively. Total QALYs were 9.86, 9.91, 9.85, and 9.83, 
respectively. Denosumab had an incremental cost-effectiveness ratio (ICER) of 
€5,283 compared to alendronate and dominated risedronate and ibandronate. 
Results were most sensitive to changes in relative risk (RR) of hip fracture with 
denosumab, cost of denosumab and RR of vertebral fracture with denosumab. 
The probability of denosumab being cost-effective compared to oral 
bisphosphonates at a threshold of €66,000/QALY was 85.5%. In a sensitivity 
analysis of offset time of 5 years for oral bisphosphonates, denosumab had an 
ICER of €10,382 compared to alendronate. CONCLUSIONS: Denosumab is cost-
effective compared to branded and generic oral bisphosphonates in the Swedish 
MOP population.  
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Schabert VF1, Yeaw J2, Korn J3, Quach C4, Harrison DJ5, Yun H6, Joseph G5, Collier D7, 
Curtis J6 
1IMS Health Consulting Group, Alexandria, VA, USA, 2IMS Health, Alexandria, VA, USA, 3IMS 
Health, Waltham, MA, USA, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 
5Amgen, Inc., Thousand Oaks, CA, USA, 6University of Alabama at Birmingham, Birmingham, 
AL, USA, 7Amgen, Thousand Oaks, CA, USA  
OBJECTIVES: Rheumatoid arthritis (RA) guidelines say little regarding optimal 
treatment after first-line biologics. We applied a published claims-based 
algorithm to estimate treatment effectiveness (as a proxy for low disease activity 
or remission) and cost per responder in US managed care patients with RA who 
switched to a new biologic after previously initiating etanercept, adalimumab, 
infliximab, golimumab, or abatacept, for first-line treatment of moderate to 
severe RA. METHODS: Data were obtained from IMS PharMetrics Plus™, which 
comprises adjudicated medical and pharmaceutical claims for 150 million 
enrollees (40 million annually). An initial cohort included patients with RA aged 
18-63, initiating biologic treatment 2007-2010, without diagnoses for other 
approved indications for these biologics, without any biologic use in the 6 
months before initiation, and enrolled 12 months after initiation. The subset of 
patients who switched to a second biologic within 1 year of initiation (and before 
3/21/2011) and were enrolled an additional year after switching, and had ≥100 
patients were eligible for this analysis. The algorithm defined lack of 
effectiveness as: medication possession ratio (MPR) <80% (or fewer infusions 
than specified on US label), increase in biologic dose or frequency, switching 
biologics, adding new non-biologic Disease Modifying Anti-Rheumatic Drugs, 
initiation or increase of glucocorticoid dose, or >1 parenteral or intra-articular 
injection. RESULTS: Of 16,011 initial cohort patients, 1,243 met criteria for this 
analysis and switched to: etanercept (n=318), adalimumab (n=527), infliximab 
(n=202), and abatacept (n=196). Mean age at switch was 48.9 (SD 9.9), 80.2% were 
female. Post-switch biologics met algorithm critiera for “effective” in 22% of 
etanercept, 11% of infliximab, 21% of adalimumab, and 25% of abatacept 
patients. Cost per responder was $64,449 for etanercept, $226,167 for infliximab, 
$71,877 for adalimumab, and $87,563 for abatacept. CONCLUSIONS: Although 
abatacept was more effective second line than the other agents, the cost per 
responder was lower for etanercept and adalimumab.  
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OBJECTIVES: A recently published claims-based algorithm to evaluate effectiveness 
of biologics for rheumatoid arthritis (RA) was validated using data from the Veteran 
Health Administration and VA RA registry. The objective was to compare 1-year 
cost per responder among biologics approved for first-line treatment of moderate to 
severe RA, etanercept, adalimumab, infliximab, golimumab, and abatacept among 
patients in a US health plan using this claims-based algorithm. METHODS: This 
retrospective cohort study used commercial claims data from the Optum Research 
Database, including medical and pharmacy claims for >13.3 million individuals. 
Adult patients with RA (ICD-9 714.0x) newly initiating biologic treatment between 
Jan 1, 2008 and Dec 1, 2010 followed by ≥12 months of continuous enrollment were 
included. Patients with other diagnoses for which these agents are approved were 
excluded. The algorithm classifies a drug as “non-effective” if any of the following 
criteria are met: low adherence MPR < 80% or receiving less than the expected 
number of infusions/injections; increase in biologic dose or frequency; switching 
biologics; adding new non-biologic Diseases Modifying Anti-Rheumatic Drugs; new 
glucocorticoid use or increase in glucocorticoid dose; and > 1 parenteral or intra-
articular glucocorticoid injection. Drug costs were estimated using actual 
medication usage and administration costs. Non-responders were defined as 
patients in whom the drug was classified as “non-effective”. RESULTS: A total of 
5,474 patients (2,425 etanercept, 1,857 adalimumab, 773 infliximab, 295 abatacept, 
and 124 golimumab) were included. Across agents, between 76% and 85% were 
female, with a mean age of 48 years. The medications were classified “effective” 
(low disease activity or remission) in 32.7%, 27.7%, 19.0%, 30.2%, and 32.3% of 
patients respectively. Mean cost per responder was lowest for etanercept ($43,935), 
followed by golimumab ($49,589), adalimumab ($52,752), abatacept ($62,300), and 
infliximab ($101,402). CONCLUSIONS: Etanercept had the lowest cost per responder 
in RA using a new, validated claims based algorithm.  
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Elgart JF1, Gonzalez L1, Aiello EC2 
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro 
Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2Bristol-Myers Squibb, Buenos Aires, 
Argentina  
OBJECTIVES: To estimate the cost-effectiveness of abatacept in combination 
with methotrexate (MTX) versus rituximab or tocilizumab in combination with 
MTX, in patients with Rheumatoid Arthritis with inadequate response to 
methotrexate (IR-MTX) in Chile. METHODS: Adapting a previously validated 
model, dynamic simulation techniques and clinical data from published 
literature were used to compare the clinical events, quality of life, and direct 
medical costs of abatacept, rituximab and tocilizumab. Costs of drug acquisition, 
administration and monitoring were considered. Costs were expressed in US 
Dollars of 2012 (Exchange rate: $ 487.8 Chilean pesos=1 US Dollar). A 5-year time 
horizon for a cohort of 1000 patients and the payer’s perspective were assumed. 
Costs and health outcomes were discounted at 6% annually. Univariate 
sensitivity analysis was performed to assess the robustness of the model results. 
RESULTS: A hypothetical cohort of 1,000 patients with RA and IR-MTX in Chile, 
followed for 5 years, resulted in mean drug costs of: US$40,792, US$21,952, and 
US$35,849, for abatacept, rituximab and tocilizumab, respectively. Total direct 
medical costs (discounted) per patient were US$47,533 (46,510-48,848) for 
abatacept, US$27,428 (27,017-27,914) for rituximab, and US$ 42,543 (41,545- 
44,428) for tocilizumab. The total QALYs gained (discounted) by abatacept, 
rituximab and tocilizumab during the same period were: 2.06 (2.01-2.10), 1.11 
(1.07-1.16) and 1.93 (1.87-1.97) respectively. The calculated Incremental Cost-
Effectiveness Ratio (ICER) for abatacept compared to rituximab and tocilizumab 
were US$21,117 (18,089-25,792) and US$37,614 (9,179-185,253) per QALY gained, 
respectively. Sensitivity analysis confirmed the robustness of the model findings. 
CONCLUSIONS: In Chile, according to the model inputs, abatacept showed better 
effectiveness in terms of QALYs than rituximab or tocilizumab, for patients with 
rheumatoid arthritis after an inadequate response to MTX. The results suggest 
that abatacept is cost-effective compared to rituximab (ICER ≤3 GDP per capita).  
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OBJECTIVES: To estimate the cost-effectiveness of Abatacept in combination 
with methotrexate (MTX) versus infliximab or tocilizumab in combination with 
MTX, in patients with rheumatoid arthritis with inadequate response to 
methotrexate (IR-MTX) in Argentina. METHODS: Adapting a previously validated 
model, dynamic simulation techniques and clinical data from published 
literature were used to compare the clinical events, quality of life, and direct 
medical costs of abatacept, infliximab and tocilizumab. Costs of drug acquisition, 
administration and monitoring were considered. Costs were calculated from 
social security system of Argentina (Exchange rate: $4.41 Argentinean pesos=1 
US Dollar). A 5-year time horizon was assumed. Costs and health outcomes were 
discounted at 3% annually. Univariate sensitivity analysis was performed to 
assess the robustness of the results of the model. RESULTS: A hypothetical 
cohort of 1,000 patients with RA and IR MTX in Argentina, followed for 5 years, 
resulted in mean drug costs of: US$70,427, US$80,930, and US$85,986, for 
abatacept, infliximab and tocilizumab, respectively. Total direct medical costs 
(discounted) per patient were US$78,458 (76,543-81,290) for abatacept, US$ 89,752 
(87,705-95,250) for infliximab, and US$ 93,492 (90,916-98,903) for tocilizumab. The 
total QALYs gained (discounted) by abatacept, infliximab and tocilizumab during 
the same period were: 2.47 (2.41-2.50), 2.39 (2.34-2.43) and 2.39 (2.34-2.43) 
respectively. Using abatacept as the reference treatment, infliximab and 
tocilizumab provided less utility at a higher cost, being dominated by abatacept. 
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Sensitivity analysis confirmed the robustness of the model findings. 
CONCLUSIONS: This study shows that in Argentina, according to the model cost-
effectiveness results, abatacept with MTX would be dominant treatment option 
compared to infliximab and tocilizumab, for patients with rheumatoid arthritis 
after an inadequate response to MTX.  
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OBJECTIVES: Approximately 0.4% of the Latin American population over 16 years 
old is affected by Rheumatoid Arthritis (RA). RA has an important economic and 
social impact due to its chronic and progressive condition. The objective is to 
assess the cost-effectiveness (CE) of etanercept in the treatment for moderate to 
severe RA, among patients failing antirheumatic drugs, in comparison with the 
rest of anti-TNF and IL-6 blockers available in Honduras, from the health care 
payer’s perspective. METHODS: A decision-tree model was implemented to 
compare the costs and effectiveness of etanercept (comparator, 50mg/week), 
adalimumab (40mg/15 days), infliximab (3-10mg/kg), rituximab (1000mg day 0 
and 15, week 16-24) and tocilizumab (8mg/kg/month), all in combination with 
methotrexate, in the treatment of RA in adult population of Honduras. The 
effectiveness measures were: American College of Rheumatology (ACR) Response 
Criteria ACR<20 and ACR<70. Quality utilities were obtained from Health 
Assessment Questionnaire (HAQ). Local costs (2012 US$) were obtained from 
Official Social Security databases of Honduras. The outcomes were: total costs of 
RA (adverse events, exams and treatments) and QALYs gained. Univariate 
sensitivity analysis was performed. The time horizon was 2 years and the 
discount rate was 5% for costs and health outcomes. RESULTS: The total cost of 
etanercept was $US39,788.57, being $US1,149.43, $US3,131.82 $US6,622.29, and 
$US16,616.10 less expensive than tocilizumab, rituximab, adalimumab, and 
infliximab, respectively. Etanercept also gained the highest number of QALYs 
(1.5423) in comparison with adalimumab (1.5048), infliximab, (1.4299), rituximab 
(1.4674), and tocilizumab (1.4955). Cost-effectiveness analyses showed etanercept 
as the dominant strategy. Acceptability curves showed that at the willingness-
to-pay level of US$8,000/QALY, etanercept was cost-effective with a 100% 
probability. PSA results support the robustness of these findings. CONCLUSIONS: 
This is the first CE study for RA developed in Honduran population. Etanercept 
appeared as the most cost-effective alternative for RA compared to other anti-
TNF and IL-6 blockers.  
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OBJECTIVES: Administrative claims contain detailed medication, diagnosis, and 
procedure data, but their lack of clinical outcomes for rheumatoid arthritis (RA) 
has limited their use in comparative effectiveness research. A validated claims-
based algorithm uses adherence, dosing, and treatment modifications to 
estimate biologics’ effectiveness (low disease or remission) for RA. The objective 
was to implement this algorithm in a US managed-care database and calculate 
the cost per algorithm-defined responder among biologics approved for 
moderate to severe RA (etanercept, adalimumab, infliximab, golimumab, 
abatacept). METHODS: Data were obtained from the IMS PharMetrics Plus™ 
Database, comprised of adjudicated medical and pharmaceutical claims for 150 
million unique enrollees. The cohort included patients with RA aged 18-63, 
initiating treatment between January 2007 and December 2010, without RA 
biologics 6 months before first treatment, and enrolled between 6 months before 
and 12 months after first biologic. Other TNF responsive conditions were 
excluded. The algorithm defines lack of effectiveness as: medication possession 
ratio < 80% (or fewer infusions/injections than specified on US label), increase in 
biologic dose or frequency interval, switching biologics, adding new non-biologic 
Disease Modifying Anti-Rheumatic Drugs, glucocorticoid use, initiation or 
increase of glucocorticoid dose, or > 1 parenteral or intra-articular injection 
during the follow-up period. Drug and administration costs were obtained from 
allowed amounts on claims. RESULTS: The cohort included 16,011 patients, 
mean age 49.3, 76.7% female. Algorithm effectiveness (low disease or remission) 
criteria were met in 31.0% of etanercept (n=7,247), 28.6% of adalimumab 
(n=4,991), 20.2% of infliximab (n=2,352), 28.6% of abatacept (n=1,160), and 27.2% 
of golimumab (n=261) patients in the first 12 months of treatment. Mean first 
year cost per responder was lowest for etanercept ($50,141), followed by 
golimumab ($53,386), adalimumab ($56,941), abatacept ($73,516), and infliximab 
($114,089). CONCLUSIONS: Etanercept had the highest estimated effectiveness 
and lowest cost per responder among first-line RA biologics using a new, 
validated claims-based algorithm.  
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OBJECTIVES: Rheumatoid arthritis (RA) affects approximately 40,000 people in 
Costa Rica. It is associated with a significant effect on the patients’ quality of life 
and costs to society. The aim is to assess the cost-effectiveness of etanercept in 
the treatment for moderate to severe RA, among patients failing previous 
antirheumatic therapy (DMARDS), in comparison with the rest of anti-TNF and 
IL-6 blockers products in Costa Rica, from the health care payer’s perspective. 
METHODS: A decision tree model was used to compare the costs and 
effectiveness of the alternatives, all in combination with methotrexate, in the 
treatment of RA in adult population of Costa Rica. The alternatives included 
were: etanercept (comparator, 50mg/week), adalimumab (40mg/15 days), 
infliximab (3-10mg/kg), rituximab (1000mg day 0 and 15, week 16-24) and 
tocilizumab (8mg/kg/month). The effectiveness measures were: American 
College of Rheumatology (ACR) Response Criteria ACR<20 and ACR<70. Quality 
utilities were obtained from Health Assessment Questionnaire (HAQ). Local costs 
(2012 US$) were obtained from Costa Rica Social Security databases. The 
outcomes were expressed as total costs of RA and quality-adjusted life years 
(QALYs) gained. Univariate sensitivity analysis was performed. The time horizon 
was two years and the discount rate was 5% for costs and health outcomes. 
RESULTS: Results showed that etanercept gained the highest number of QALYs 
(1.5423) in comparison with adalimumab (1.5048), infliximab, (1.4299), rituximab 
(1.4674), and tocilizumab (1.4955). Etanercept appeared as the least expensive 
option (US$38,836.32) while infliximab resulted as the most expensive option 
(US$57,237.22). Cost-effectiveness analyses exhibited etanercept as the dominant 
strategy. Acceptability curves showed that at the willingness-to-pay level of 
US$10,000/QALY, Etanercept was cost-effective with a 100% probability. 
Probability sensitivity analysis results support the robustness of these findings. 
CONCLUSIONS: Etanercept is the most cost-effective alternative for treating RA 
among other anti-TNF and IL-6 blockers.  
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OBJECTIVES: Rheumatoid arthritis (RA) affects approximately 60.000 people in El 
Salvador. RA has a significant effect on quality of life of patients and it is 
associated with high costs to society. The objective is to assess the cost-
effectiveness (CE) of etanercept in the treatment for moderate to severe RA, 
among patients failing previous antirheumatic drugs (DMARDs), in comparison 
with the rest of anti-TNF and IL-6 blockers products available in El Salvador, 
from the health care payer’s perspective. METHODS: In order to compare the 
costs and effectiveness of the alternatives included, a decision-tree was utilized. 
The alternatives for treating RA were: etanercept (comparator, 50mg/week), 
adalimumab (40mg/15 days), infliximab (3-10mg/kg), rituximab (1000mg day 0 
and 15, week 16-24) and tocilizumab (8mg/kg/month), all in combination with 
methotrexate. The effectiveness measures were: American College of 
Rheumatology (ACR) Response Criteria ACR<20 and ACR<70. Quality utilities 
were obtained from Health Assessment Questionnaire (HAQ). Local costs (2012 
US$) were obtained from official databases from the Social Security of El 
Salvador. The outcomes were: total costs of RA and quality-adjusted life years 
(QALYs) gained. Univariate sensitivity analysis was performed. The time horizon 
was 1 year. RESULTS: Etanercept was the least expensive option ($US19,959.82) 
while infliximab was the most expensive option (US$25,262.66). The total cost for 
Adalimumab was $US21,236.14 and $21,301.85 for Rituximab. Etanercept gained 
the highest number of QALYs (0.79) compared to adalimumab (0.77), infliximab, 
(0.73), and rituximab (0.75). In the CE analyses, etanercept appeared as the 
dominant strategy. Acceptability curves showed that at the willingness-to-pay 
level of US$15,300/QALY, etanercept was cost effective with a 100% probability. 
Probability sensitivity analysis results support the robustness of these findings. 
CONCLUSIONS: Etanercept is the least expensive and most effective option for 
treating RA in El Salvador. Etanercept is cost-effective option according to <3 GDP 
per capita ($7,600; 2011) threshold of El Salvador.  
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Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for osteoarthritis 
(OA). All NSAIDs treatment carries gastrointestinal (GI) toxicity risk, ranging from 
mild dyspepsia to GI hemorrhage and perforation. Treatment with gastric 
mucosa protectors like potassium pump inhibitors (PPI) had been associated 
with long NSAID treatment to reduce GI toxicity. OBJECTIVES: To evaluate the 
cost-effectiveness and cost-utility of fixed-dose-combination (FDC) of 
naproxen/esomeprazole, NSAIDs or cyclooxygenase-2 inhibitors’ (COX-2) in 
chronic users at risk of gastropathy. METHODS: A Markov model was developed 
with a 3-month cycle during 1 year horizon. Health states represent adverse 
events (AE) GI and cardiovascular (CV); the risk of experiencing an AE and 
moving between different health states was taken from published clinical 
research. The model estimates the net impact of the treatment alternatives 
